One step forward, two steps back: The story of everolimus in advanced breast cancer-Reference-Cited by-同舟云学术

One step forward, two steps back: The story of everolimus in advanced breast cancer

Published:2015-10 Issue:5 Volume:24 Page:529-531
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Niraula Saroj,Ocana Alberto,Amir Eitan

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference11 articles.

1. Hallmarks of cancer: the next generation;Hanahan;Cell,2011

2. risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis;Niraula;J Clin Oncol,2014

3. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N. Engl J Med,2012

4. Everolimus plus exemestane for hormone receptor-positive (hr+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2. EBCC-9; 19–21;Piccart,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomolecular Prospecting, Informative Gaps, and the Cancer Clinic: A Qualitative Fieldwork and an Epistemological, Historical and Ethical Analysis of Informed Consent for Clinical Trials for Monoclonal Antibodies and Biobank Research;Frontiers in Genetics;2022-06-13

2. Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer;npj Breast Cancer;2018-06-26

3. Synthesis and evaluation of an injectable everolimus prodrug;Bioorganic & Medicinal Chemistry Letters;2017-03

4. Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy;Cancer Treatment Reviews;2016-11